OTC Claritin Access Needs Study Before Other Switches Are Forced – Pfizer
This article was originally published in The Tan Sheet
Executive Summary
FDA should evaluate whether OTC Claritin has increased access and lowered costs for allergy sufferers before deciding whether to require the other second-generation antihistamines to switch OTC, Pfizer asserts in May 7 comments to the agency
You may also be interested in...
Forced OTC Switch Impact On Consumers “Ambiguous” – MIT’s Berndt
The impact of forced Rx-to-OTC switches on consumers "is uncertain and ambiguous and there is no clear gain in social welfare," MIT economics professor Ernst Berndt, PhD, says in recent comments to FDA
Forced OTC Switch Impact On Consumers “Ambiguous” – MIT’s Berndt
The impact of forced Rx-to-OTC switches on consumers "is uncertain and ambiguous and there is no clear gain in social welfare," MIT economics professor Ernst Berndt, PhD, says in recent comments to FDA
Forced OTC Switch Impact On Consumers “Ambiguous” – MIT’s Berndt
The impact of forced Rx-to-OTC switches on consumers "is uncertain and ambiguous and there is no clear gain in social welfare," MIT economics professor Ernst Berndt, PhD, says in recent comments to FDA